Anavex Life Sciences Corp (AVXL)

[TrueTrades]

Negatives?

*Lack of partnership could mean 100%+ dilution for financing.

*A2-73 may not demonstrate enough statistical improvement in cognition and function over the SOC to be approved.

*Sigma-1/mixed muscarinic compounds may not succeed on the whole as a viable class of therapeutics.

*Long term use may lead to serious AEs and safety concerns which are not apparent yet.

*Sufficient IP protection may not be achieved.

*Market forces may succeed in crushing the spirit and perseverance of the company.

*90% of neurological drugs fail in advanced trials.

On and on and on. It is an uphill battle against seemingly overwhelming odds. We get daily reminders of that.
§